Full-Time
Posted on 3/16/2025
Provides scientific tools for life sciences
No salary listed
Entry, Junior
Glasgow, UK
LGC Group is a global leader in the life sciences sector, providing scientific tools and solutions that support advancements in healthcare and pharmaceuticals. The company offers a variety of products, including oligo components, probes, primers, and recombinant viral materials, which are essential for detecting diseases and developing vaccines and therapies for conditions like cancer, heart disease, diabetes, asthma, and infectious diseases such as COVID-19, Ebola, and Zika. LGC's products work by enabling accurate testing and analysis in clinical laboratories and pharmaceutical companies, helping to ensure the safety and effectiveness of medical treatments. What sets LGC apart from its competitors is its strong focus on quality and innovation, which allows it to deliver high-quality scientific tools that meet the needs of a diverse range of clients. The company's goal is to drive improvements in healthcare outcomes and contribute to a safer world through its scientific advancements.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
London, United Kingdom
Founded
1841
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
Remote Work Options
Graham B Jackson Pty Ltd (GBJPL), an Australian leader in reference materials, partners with the globally renowned LGC Group to supply high-quality CRMs to laboratories across the country.
For example, LGC Group introduced a proficiency testing (PT) service in April 2020 that uses nucleic acid amplification testing to identify SARS-CoV-2 (COVID-19).
UK-based LGC, an international life sciences measurement and tools company, has appointed Joydeep Goswami as president and CEO, succeeding Euan O'Sullivan, who decided to step down from his role in early 2024 after fourteen years of service.
London, UK – 4 December 2024 – LGC today announces an addition to its growing global clinical diagnostics and genomics portfolio, following the acquisition of DiaMex, a manufacturer of third-party serology and molecular quality controls used in clinical laboratories and blood banks across the world.
LGC acquires DiaMex to drive innovation and choice for core laboratory customers: acquisition complements LGC's serology and molecular quality control portfolio and enhances choice of products from a single supplier.